Skip to main content
Premium Trial:

Request an Annual Quote

BioSkryb Genomics Licenses Amplification Tech to CooperSurgical

NEW YORK – BioSkryb Genomics said on Tuesday that it has licensed its genomic amplification technology to CooperSurgical for use in preimplantation genetic testing.

Under the multi-year global agreement, BioSkryb will license its ResolveDNA single-cell genomic amplification technology to CooperGenomics, a unit of CooperSurgical, which will exclusively market and distribute the technology in the women's reproductive health market.

Financial and other terms of the deal were not disclosed.

"Having access to the BioSkryb technology will provide a new level of genomic analysis and testing accuracy, enhancing the positive impact we have in the field of women’s reproductive health and in the lives of patients around the world," Charles Smith, executive VP of life sciences services and innovation at CooperGenomics, said in a statement.

Founded in 2018 and based in Durham, North Carolina, BioSkryb is commercializing a proprietary flavor of primary template-directed amplification, licensed from St. Jude Children's Research Hospital.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.